HRE Luciferase Reporter Lentivirus | 78668

HRE Luciferase Reporter Lentivirus | 78668 | Gentaur US, UK & Europe Disrtribition

Category: Immunotherapy/Viral Tools

Application: Screen for activators or inhibitors of hypoxia-related signaling pathways Generate an HRE luciferase reporter stable cell line (puromycin resistant) following puromycin selection and limiting dilution

Background: Hypoxia occurs in solid tumors as a result of poor vascularization within the core of the tumor. It is a driver of tumor progression and resistance to therapy through adaptive responses. Hypoxia response elements (HREs) are transcription factor binding sites within the promoters of various genes regulated by hypoxia-inducible factors (HIFs). As oxygen becomes rate limiting, HIFs form heterodimers that recognize cognate HREs, thus activating the transcription of genes involved in cell proliferation, metastasis, and angiogenesis. HIF activation in many types of cancer correlates with poor outcomes.

Description: The Hypoxia Response Element (HRE) Luciferase Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce most types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by four copies of a hypoxia response elements (HRE) located upstream of the minimal TATA promoter (Figure 1) and an antibiotic selection gene (puromycin) for the selection of stable clones. After transduction, the induction of hypoxia in the target cells can be monitored by measuring the luciferase activity.

Product Type: Viral Tools

Shippement Condition: -80°C